Unknown

Dataset Information

0

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects.


ABSTRACT: This study compared the pharmacokinetics of a fixed-dose combination (FDC) of candesartan (16 mg) and amlodipine (10 mg) versus coadministration of individual formulations to clarify the bioequivalence of the FDC. In this randomized, open-label, single-dose, 2-treatment, 2-way crossover study, healthy Korean volunteers received a single dose of candesartan (16 mg) with amlodipine (10 mg) as either an FDC or single agents concomitantly administered, with a 2-week washout period. Serial blood samples were collected up to 72 hours after dosing for each treatment period, and plasma concentrations of candesartan and amlodipine were measured using a validated liquid chromatography-tandem mass spectrometry method. A total of 39 subjects completed the study. The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for the area under the plasma concentration-time curve from time 0 to the last measurement (AUC0-t) and the peak plasma concentration (Cmax) for candesartan were 1.0182 (0.9562-1.0841) and 0.9492 (0.8726-1.0324), respectively. The GMR and 90% CI for the AUC0-t and Cmax for amlodipine were 1.0552 (1.0255-1.0857) and 1.0668 (1.0259-1.1094), respectively. In conclusion, the new FDC formulation of candesartan (16 mg) and amlodipine (10 mg) was bioequivalent to the concomitant administration of single agents. A single dose of candesartan/amlodipine as the FDC or as single agents was well tolerated. Trial Registration:ClinicalTrials.gov Identifier: NCT02988362.

SUBMITTER: Lee HW 

PROVIDER: S-EPMC7327189 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects.

Lee Hae Won HW   Kang Woo Youl WY   Jung Wookjae W   Gwon Mi-Ri MR   Yang Dong Heon DH   Kim Eun Hee EH   Cho Kyunghee K   Yoon Young-Ran YR   Seong Sook Jin SJ  

Translational and clinical pharmacology 20200624 2


This study compared the pharmacokinetics of a fixed-dose combination (FDC) of candesartan (16 mg) and amlodipine (10 mg) versus coadministration of individual formulations to clarify the bioequivalence of the FDC. In this randomized, open-label, single-dose, 2-treatment, 2-way crossover study, healthy Korean volunteers received a single dose of candesartan (16 mg) with amlodipine (10 mg) as either an FDC or single agents concomitantly administered, with a 2-week washout period. Serial blood samp  ...[more]

Similar Datasets

| S-EPMC2801628 | biostudies-literature
| S-EPMC8473943 | biostudies-literature
| S-EPMC6851892 | biostudies-literature
| S-EPMC7003954 | biostudies-literature
| S-EPMC7547973 | biostudies-literature
| S-EPMC5846630 | biostudies-literature
| S-EPMC7234962 | biostudies-literature
| S-EPMC5857156 | biostudies-literature
| S-EPMC7028125 | biostudies-literature
| S-EPMC7408357 | biostudies-literature